FDA Clears First BAFF/APRIL Blocker for Kidney Disease Linked to Autoimmunity
IgA nephropathy is a kidney disease caused by an autoimmune process in which abnormal antibody deposits build up in the kidneys' filtering structures, gradually damaging them and often leading to significant protein loss in the urine, a marker doctors watch closely because it tracks with long-term kidney decline. It's considered a rare disease, but for the people who have it, treatment options that specifically target the underlying immune process, rather than just managing blood pressure and general kidney health, have been limited.
On July 7, 2026, Vera Therapeutics announced that the FDA granted accelerated approval to Trutakna (atacicept-vymj) for adults with primary IgA nephropathy who are at risk of disease progression. Trutakna is notable as the first available therapy that binds both BAFF, B-cell activating factor, and APRIL, a proliferation-inducing ligand, two signaling proteins that sit further upstream in the immune process believed to drive IgA nephropathy, rather than targeting a single downstream piece of the puzzle. It's given as a 150mg injection, self-administered by patients at home once weekly using an autoinjector.
The approval was based on a prespecified interim analysis of the ORIGIN 3 trial, in which patients treated with atacicept achieved a 46% reduction from baseline in proteinuria, a statistically significant 42% greater reduction than those on placebo, measured at 36 weeks. That's a meaningful drop in a key marker doctors use to judge whether kidney damage is likely to continue progressing.
It's important to understand exactly what accelerated approval means here. This pathway allows the FDA to approve a drug based on a marker, in this case proteinuria reduction, that's reasonably likely to predict real clinical benefit, before that benefit has been definitively proven in a completed, longer-term trial. It has not yet been established whether Trutakna actually slows the long-term decline in kidney function itself, and continued approval could depend on a confirmatory trial verifying that clinical benefit down the road.
For patients with primary IgA nephropathy, particularly those already showing signs of progression, this gives doctors a genuinely new tool that works through a different immune mechanism than existing options, with the convenience of at-home, self-administered weekly dosing. As with any accelerated approval, it's worth having a candid conversation with your nephrologist about what the current evidence does and doesn't yet show, and what the confirmatory trial results might mean for your continued treatment down the line. Given how few IgA nephropathy treatments target the immune process this far upstream, this is a development worth tracking even if you're not an immediate candidate today.